Panelists at the Africa Young Innovators for Health Award Ceremony, held on Thursday.

Africa has the highest entrepreneurship rate in the world, yet greater financial resources are needed to ensure that innovation can be implemented to strengthen health systems and the welfare of health workers, said panellists at an innovation award ceremony on Thursday.

The Africa Young Innovators for Health Award, co-organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa, launched its first competition this year designed to highlight and support the work of pioneering young African entrepreneurs in the field of health innovations, particularly healthcare solutions to support healthcare workers. 

Attracting over 300 entries from 33 countries, the winners had developed innovations to assist in cancer diagnosis, health worker development and patient record retrieval.

Winner Dr Conrad Tankou, CEO of Global Innovation and Creativity Space in Cameroon, developed GICMED, a suite of medical technologies that helps to screen and diagnose breast and cervical cancer in women. 

Dr Conrad Tankou, CEO of Global Innovation and Creativity Space, won first place for the Africa Young Innovators for Health Award.

Breast and cervical cancer account for 50% of all new cancers in Sub-saharan African women. Healthcare workers can be trained to use the technology to remotely screen women with real-time pathology confirmation and connect them to a point of care for treatment. 

“It is an honour to receive the first-ever Africa Young Innovators for Health Award,” said Tankou. “With the Award’s financial and business mentorship support, we can upgrade our technologies and start scaling our solution much quicker by investing in manufacturing capabilities and building more local partnerships.”

In second place was John Mwangi, CEO of Daktari Media Africa in Kenya, who established Daktari Online, which provides a professional development platform for healthcare workers. 

John Mwangi, CEO of Daktari Media Africa, won second place for the Africa Young Innovators for Health Award.

Currently 13,000 health workers use the platform and it has been accredited by the regulatory bodies for pharmacists, pharmaceutical technologists, and physician assistants.

“The practice of medicine requires continuous updating…and that’s what we seek to do,” said Mwangi. “We said why don’t we just democratize [access to information and professional development] and have this accessible to people even from remote areas.”

The third-place winner, Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, developed an artificial intelligence (AI) powered electronic medical record system – Mediverse – that utilizes blockchain to help healthcare workers input and retrieve patient records. 

Dr Imodoye Abioro, CEO of Healthbotics in Nigeria, won third place for the Africa Young Innovators for Health Award.

The technology could work on any device and even in places where the internet has not yet reached.

“We do not have enough healthcare workers for the disease burden we’re battling,” said Abioro. “The first thought we had was how do we make the healthcare worker more effective, how can he or she see more patients, how can he or she be smarter or faster.”

“Mediverse is what we consider to be a solution that will be necessary for us to build a sustainable healthcare infrastructure in Africa upon,” Abioro added.

“This could really revolutionize the way that healthcare workers are able to access the data they need about their patients in real time,” said Nicole Kayode, CEO and Founder of Medixus. 

The winners take home between US$15,000 and US$40,000 and will benefit from a business mentorship program, media exposure, technical training on intellectual property protection, and expert advice from an extensive network of stakeholders working across healthcare mediums.

More investment needed

Some 22% of Africa’s working-age population are starting businesses, “yet more investment in human capital is needed for this demographic potential to reap the development rewards it should,” said Thomas Cueni, Director-General of IFPMA.

“We are confident that the winners of the African Young Innovators for health award will contribute to improving health systems and growing African economies,” added Cueni. 

“We don’t lack ideas or creativity, that’s not what’s missing,” said Dr Awa Marie Coll-Seck, Senegal’s Minister of State of Senegal and former health minister. “Among innovators, it’s often about the lack of financial resources for research…This is what stops them from concretising their ideas and developing prototypes.”

“We need to give [the young innovators] the opportunity to develop ideas and their expertise,” said Coll-Seck.

Africa is the youngest continent on the planet. By 2050, Africa’s youth population under the age of 24 will increase by nearly 50%. This presents an opportunity for rapid social and economic transformation, said the panelists. 

In 2019, sub-Saharan African countries were classified among the hundred best countries in terms of innovation.

Africa facing massive shortages in healthcare workforce

Africa bears a quarter of the global disease burden but faces a shortage of over two million healthcare professionals. Only 2% of the world’s healthcare workforce are from the continent. 

“Our world lacks about 18 million health workers globally and…Africa is the place that really suffers the most from it,” said Pape Gaye, President Emeritus of IntraHealth International, addressing the awards ceremony.

The shortage of human and financial resources invested in the African healthcare system is putting a strain on healthcare workers and the broader national and regional health infrastructure.

“COVID-19 has laid bare the underlying inequities and prejudices in existing healthcare,” said Dr Moredreck Chibi, the World Health Organization’s (WHO) Africa Advisor for Innovation. “Our young people [need to] take the bull by its horn and apply their intellectual capital to address some of these challenges.”

Dr Moredreck Chibi, WHO Regional Advisor for Innovation for the Regional Office for Africa.

“Only this approach will ensure Africa’s sustainable path for the future of health on the continent,” said Chibi. 

“As we are all aware, the COVID pandemic has been devastating and exposed the vulnerabilities of health systems across the globe, including in Africa,” said Dr Lindiwe Makubalo, WHO Assistant Regional Director for Africa. “There could be no better time to draw on the rich human capital, especially among young people, to find solutions to the problems that we are facing.”

“COVID-19 has been a wake-up call for the continent. It is inevitable that we need to think outside the box to solve these problems,” said Makubalo. 

Innovation is a central component of public health

“Innovation has always been the driving force of progress in public health, from vaccines to penicillin to the mapping of the human genome,” said Cueni. “Innovations have changed the world and this has never been more evident than with the COVID-19 pandemic.”

Vaccines and treatments for COVID-19 were developed by pharma companies in record time due to large investments in research and a lot of innovation. 

“We have seen from smartphones to drones, there’s no doubt that technology and innovation are leapfrogging Africa and future young African entrepreneurs are playing a crucial role by developing creative ideas that can resolve the various health challenges on the continent,” said Cueni.

Thomas Cueni, Director General of the IFPMA, at the award ceremony on Thursday.

The panelists called on countries to support efforts and innovations of the youth by harnessing domestic resources through advocacy for partner financing and the creation of platforms to showcase initiatives.

Partnerships with private sector are essential

“We all know that innovation is best when it is tailored to the local context and that we should think about those who need it most when we’re creating them, and how we can create the most impact,” said Yacine Djibo, Founder and Executive Director of Speak Up Africa. 

Yacine Djibo, Founder and Executive Director of Speak Up Africa.

Building science, technology, and innovation capacity, as well as stimulating the existing entrepreneurial culture in Africa should be a priority, said Djibo. 

Collaboration with the private sector will increase the opportunities for innovation and help the continent build sustainable health systems.

“Health system strengthening and the potential of Africa’s private sector are crucially important for unleashing the entrepreneurial power of Africa’s young people,” said Cueni. “This will create innovative and compelling modern businesses, increase the capacity for these businesses to compete regionally and globally, attract both domestic and foreign investment, and diversify investment profiles.”

This will contribute to job creation and economic growth across the region.

“By leveraging its resources, expertise, networks, infrastructure, and assets, the private sector can focus on innovation for new technologies, systems, and processes, [and] can influence policy and form partnerships that will have continent-wide impact on the populations,” said Cueni. 

“We are extremely impressed by the quality of the applications we received. These applications are a shining example that young Africans are bursting with creativity and are constantly looking for local-based solutions that work,” said Djibo.

With only one-fifth of applications to the innovation award coming from women, the IFPMA and Speak Up Africa have launched the Women Innovators Incubator to address the gaps in female-led innovation. Three female participants will receive financial support, mentorship, media training, expert advice on intellectual property protection, and access to a network of global health experts.

Image Credits: Africa Young Innovators for Health Award, Africa Young Innovators for Health Award.

The South African mRNA hub aims to make Moderna-like vaccine.

Countries with high COVID-19 vaccination rates have pre-purchased over two billion excess vaccine doses, limiting the supplies available for low- and middle-income countries (LMIC).

This emerged from a meeting on Thursday between the heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization – the multilateral Task Force – and CEOs of leading vaccine manufacturing companies.

Meanwhile, the South African mRNA technology transfer hub set up in July to enable Africa to manufacture its own vaccines is moving ahead with plans to make a “Moderna-like” vaccine – despite a lack of co-operation from either mRNA manufacturer, Moderna or Pfizer-BioNTech.

This was confirmed to Health Policy Watch by Dr Marie-Paule Kieny, Chair of the Board of the Medicines Patent Pool in Geneva and President of the French Scientific Committee on COVID-19 vaccines.

“The mRNA hub doesn’t need direct transfer of technology from Pfizer/BioNTech or Moderna, as enough information on production process is available publicly and as there are no patent on mRNA vaccines in any African country,” said Kieny, who recently visited South Africa to work with local hub partners.

“The hub will therefore work with technical experts to recreate a new ‘Moderna-like’ vaccine,” added Kieny.

Appeal to swap doses, deliver to COVAX and AVAT

To alleviate COVID vaccine shortages in LMICs, the task force called on wealthy countries to urgently “swap their near-term delivery schedules with COVAX and the African Vaccine Acquisition Task Force (AVAT)”, meet their dose donation pledges with “unearmarked upfront deliveries to COVAX”, and release vaccine companies from options and contracts to enable these doses to be delivered to LMICs. 

Without these urgent steps, the world is unlikely to meet the WHO’s target of vaccinating 40% of the global population by the end of the year.

“Despite adequate total global vaccine production in the aggregate, the doses are not reaching LMICs in sufficient amounts, resulting in a crisis of vaccine inequity,” the task force said.

It also appealed for transparency about the supply of vaccines, calling on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. 

It also called on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines, raw materials and supplies.

The task team welcomed the pharmaceutical CEOs’ willingness to ‘work collectively to end vaccine inequity” and “readiness” to form a joint technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries.

However, the big pharmaceutical companies have been unwilling to work with the mRNA hub.

‘No point’ in mRNA transfer

In response to a Health Policy Watch question, Pfizer CEO Albert Bourla said that he didn’t see the point as the tech transfer “would take years”, and that producing mRNA vaccines was what Pfizer did. 

Kieny confirmed that the Medicines Patent Pool, WHO and others had reached out to the mRNA vaccine manufacturers “but up to this point, the companies have not been interested”.

Vaccine manufacturers are apparently wary of new manufacturers competing for raw materials and customers.

Shortly after the mRNA hub was announced, Pfizer revealed that it had made a deal with South African pharmaceutical company and hub member Biovac, to “fill and finish” around 100 million vaccines destined for Africa. 

Kieny described this as “an excellent step forward”, as Biovac will receive technology transfer from Pfizer for the fill-finish part of their mRNA vaccine, “especially as the Pfizer contract does not claim exclusivity”. 

“Biovac will therefore also become the first African manufacturer with a product resulting from technology transfer of the full production cycle from the hub,” said Kieny.

Image Credits: Gavi .

Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health and chair of the WHO Working Group on Sustainable Finance.

For a long time, the World Health Organization (WHO) has experienced immense financial stress resulting in numerous debates on how to remedy its economic woes. A working group set up earlier this year has been tasked with finding long-term solutions.

Each year the representatives of some 194 countries make demands on what work should be carried out by the WHO, but the money needed to carry out the requests is severely lacking.

Björn Kümmel, deputy head of the global health division at Germany’s Federal Ministry of Health, and chair of WHO’s Working Group on Sustainable Funding, recalls explaining the situation to his daughter who asks what the money problem is.

“The family decides to have breakfast with lots of friends. We need to buy 20 buns from the bakery, and there’s a plan in place because we know our guests want different buns. I send my daughter to the bakery to buy 20 different buns but only give her enough money for two,” he says.

Without enough money, Kümmel’s daughter would have to beg for money on the way to the store. Some generous passersby might give her some change, but on the condition that she spends it on specific types of buns. She might be able to bring back home all 20 buns but to a large extent they will not be the ones ordered.

“It sounds absurd when we put it this way but the member states of the WHO, in the same way, do not provide the finances to fund their own priorities agreed to by these countries,” Kümmel told Geneva Solutions.

Increasingly, individual donors have been providing funding money for these “buns”, but often face criticism for financing projects that personally interest them.

Meanwhile, the funds needed to execute the activities of the ever-broadening agenda set by the World Health Assembly (WHA) are lacking. COVID-19 has revealed major discrepancies between the expectations of the WHO and its de facto ability. “The pandemic has shown that we need a strong WHO, now more than ever, and it is clear that it is not strong enough,” Kümmel said.

Sustainability lens

For years discussions have circled around WHO’s funding, prompting its Director-General, Dr Tedros Adhanom Ghebreyesus, to reflect on how these conversations have “remained rather abstract” in a report delivered to the Executive Board.

As a result, the WHO created the Working Group on Sustainable Financing (WGSF), which is tasked with finding long-term solutions to the body’s financial troubles.

Kümmel notes that although finances remain a popular topic amongst the organisation’s members, this is the first time a “sustainability” lens is being adopted. He adds that everyone shares the view that a stronger WHO is needed, which requires more stable sources of long-term funding.

The alternative, continuing with the status quo, poses a threat to global health security and the achievement of the Sustainable Development Goals.

“There needs to be a completely new approach to ensure the WHO has the right finances in place in order to fulfil the world’s expectations,” he says.

The WSFG is working on a proposal that will “enable WHO to have the robust structures and capacities needed to fulfil its core functions,” as highlighted in the meeting report. The final report and recommendations will be taken forward to the WHO’s executive board in January 2022.

Concluding their third and most recent meeting in June, the group has already explored different financing models, including other global health actors’ funding structures that could help recharge the WHO’s coffers, drawing on lessons from other health actors.

Adopting the Global Fund’s so-called replenishment model, for example, would mean raising funds in multi-year cycles. Kümmel says the WHO budget could at least be partially funded this way.

Dr Tedros addressing the WHO’s 149th Executive Board meeting

Since taking office in 2017, Ghebreyesus has made broadening the WHO’s funding base one of the organisation’s main priorities. In 2019, he announced plans to establish the WHO Foundation to secure funds from the public, individual major donors and corporate partners.

The launch of the independent grant-making body came amid controversy over former US President Donald Trump’s decision to halt funding from the US, the WHO’s single largest donor.  The move was later reversed by current President Joe Biden but it had already exposed the health organisation’s heavy dependence on a few major donors.

Approved for 2020-2021, the budget is $5.8 billion, which reflects a $1.4bn increase from the previous biennium, mostly needed for the Covid-19 response. About 16 per cent of this figure stems from mandatory payments known as assessed contributions, paid by its members, which over the last two decades or so, have remained flat at one billion US dollars.

The other way is through voluntary contributions, secured from governments, other UN agencies and the private sector, which make up the majority of the budget.

In recent years the top voluntary contributors, in addition to the US, have included the United Kingdom, Germany and the Bill and Melinda Gates Foundation.

Yet, private players such as the Gates Foundation have come under fire for having some of the most powerful and influential voices in global health, raising questions about the WHO’s independence.

Praise for ‘Big Philanthropy’ donors

Kümmel, however, believes “these voluntary generous donors should be praised because they provide the needed funding in the absence of member states”.

The vast majority of funds coming from the private sector go to the Polio Eradication Initiative, he points out.

“If the WHO didn’t receive these resources, we wouldn’t even be close to an eradication of polio because many member states just don’t put the money on the table,” he adds.

In the last 10 years, the UN health agency has depended heavily on voluntary contributions, which can include both flexible funds untied to specified causes as well as money that can only be spent on activities decided by the donor. Still, in 2018/2019, almost 70 % of the overall budget was financed by funds allocated for specific purposes.

The working group has considered whether the core mandate of the WHO should be fully funded by “un-earmarked” flexible contributions, which favours the organisation’s aspired ways of working, whilst also exploring the importance of expanding the WHO’s donor base.

Following the recommendations of the Independent Panel for Pandemic Preparedness and Response (IPPPR), who share the view that two thirds of assessed contributions should be dues paid by member states, the working group are toying with the idea of whether this figure should be at least 50 per cent, a proposal that has been put forward to the regional committees, which Kümmel expressed had been received constructively and positively.

In addition, the group has put forward to the regional committees whether member states would support and agree to the proposal on increasing assessed contributions as well as adopt an incremental implementation schedule at next May’s 75th WHA.

Contributions from all member states

For Kümmel, all member states should contribute regardless of their economic status. However, he agrees that some countries experience severe financial challenges, thus the current mechanisms in place ensure financial possibilities are accounted for.

At the moment each country is assigned a share of the assessed budget through the WHO’s scale of assessments proportional to the size of its economy, but ultimately it is up to member states to fork out the money, particularly if it is un-earmarked funding.

Coordinated efforts across regions are vital, especially when faced with health crises such as the Covid-19 pandemic. If paired with the loss of funds from major contributors, the results can be devastating.

In 2020, the US fell to the third largest donor position, providing about 8% of the overall budget in the first three quarters. Biden has since restored ties with the body and in February pledged $4bn to the WHO-backed COVAX initiative to boost the equitable distribution of COVID vaccines, however, the full effect of this is yet to be seen.

Germany has similarly reinforced its support to WHO’s work and fight against COVID. Earlier this month the WHO launched its new Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has said it will make an initial $100 million investment to prop up the facility.

The Hub is said to focus on “collaborative intelligence”, where all 194 member states, scientific institutions and civil society could share information openly.

As the coronavirus has demonstrated, the world is not ready to rapidly spot and tackle potential pandemics. The working group believes preparing the health body against such future challenges with the appropriate resources is crucial.

“I think that it is quite clear that the strengthening of WHO post-COVID is a key priority for many countries including Germany. Member states who really want to strengthen WHO understand that ensuring sustainable financing to WHO is one of the key pillars of this,” Kümmel urged.

“We are very supportive of constructive multilateralism in global health. WHO is the global health forum where everyone sits at the table, all 194 Member States, it has a broad global health mandate, and it is fully inclusive.”

This article was first published by Geneva Solutions.

 

Image Credits: WHO/ Violaine Martin, WHO.

German Health Minister Jens Spahn and German Chancellor Angela Merkel have staunchly opposed the TRIPS waiver.

More than 140 former heads of state and Nobel laureates have called on the three candidates in line to be the next German chancellor to declare themselves in favour of waiving intellectual property on COVID-19 vaccines and transferring vaccine technologies.

Germany is leading the European Commission’s refusal to accept the so-called TRIPS waiver proposal put forward by South Africa and India at the World Trade Organisation (WTO).

However, German elections on 26 September could unseat Angela Merkel’s ruling Christian Democratic Union Party, which has steadfastly opposed the TRIPS waiver – apparently in support of BioNTech-Pfizer.

In the letter, addressed to Annalena Baerbock, Olaf Scholz, and Armin Laschet, sent on Wednesday, the signatories stress that German support for waiving patents is vital to overcoming vaccine monopolies, transferring vaccine technology and scaling up vaccine manufacturing around the world to prevent millions more deaths from COVID-19.

Signatories include former French President François Hollande, former UK Prime Minister Gordon Brown, former Colombian President Juan Manuel Santos, former Malawian President Joyce Banda and Helen Clark, New Zealand’s former prime minister. 

Nobel prize winners include Professor Joseph Stiglitz, Professor Francoise Barre-Sinoussi and Elfriede Jelinek.

End the pandemic

They express deep concern with Germany’s “continued opposition to a temporary waiver of the World Trade Organization’s (WTO) intellectual property rules”, at a time in which “the artificial restriction on manufacturing and supply is leading to thousands of unnecessary deaths from COVID-19 each day”. Less than 2% of adults are fully vaccinated in low-income countries compared to almost 50 % in high-income countries.

The TRIPS waiver on COVID-19 vaccines, proposed by India and South Africa in October 2020, is supported by over 100 countries including the United States and France in doing so. 

“Having helped create the most successful vaccine technology against COVID-19, by overcoming pharmaceutical monopolies and insisting that the technology be shared, Germany has the ability to help end this pandemic,” according to the letter.

It also calls on the next Chancellor to ensure that German pharmaceutical companies openly and rapidly share life-saving mRNA vaccine technology with qualified producers around the world.

Commenting on the letter, New Zealand’s Clark stressed: “Germany’s support for a TRIPS waiver in the exceptional circumstances presented by COVID-19 would send a clear signal that all peoples should be able to benefit speedily from available vaccines and therapeutics. Widespread vaccination now and further scaling up of vaccine production will play a significant role in curbing the pandemic.”

Extraordinary power

Meanwhile, Nobel laureate Joseph Stiglitz, said that the new Chancellor of Germany will “hold extraordinary power to turn the tide on this horrific pandemic”. 

“Intellectual property rules are today locking out people across the world from the benefits of life-saving science – it is time for Germany to ensure the transfer of vaccine technologies and join the rest of the world in backing a temporary waiver at the WTO,” he added.

Earlier in the week, ​​Belgian Green Sarah Matthieu, a Member of the European Parliament, said that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added.

“We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network.

Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added.

The letter was coordinated by the People’s Vaccine Alliance, a coalition of more than 70 organizations including Club de Madrid, Global Justice Now and UNAIDS.

 

Image Credits: Clemens Bilan.

President Joe Biden speaking in Germany after a G7 meeting.

Pressure is mounting on US President Joe Biden to provide global leadership to ensure equitable access to COVID-19 vaccines in the face of the European Commission’s refusal to support a waiver on intellectual property rights.

Biden is expected to host a global leaders’ summit on COVID-19 alongside the United Nations General Assembly next week, and US officials are lobbying countries to support targets to end the pandemic centred on how to get 70% of people vaccinated by late 2022.

African leaders hope that Biden’s COVID-19 summit will lead to more equitable access to vaccines:

WHO & African Leaders Pin Hopes on Biden’s ‘Global COVID-19 Summit’ for ‘New Deal’ on Pandemic Response  

Negotiations over the suspension of intellectual property rights for COVID-19 vaccines, therapeutics and diagnostics, the TRIPS waiver, have stalled at the World Trade Organization (WTO) in the face of opposition from the European Union.

But if the US put forward a text on waiver, this would reinvigorate the talks, appealed South African trade ministry advisor Zane Dangor on Tuesday. South Africa and India are co-sponsors of the waiver.

“Action by the US will be particularly potent to shift the needle in the negotiations and make people come around the table and discuss these issues,” said Dangor, one of the key officials involved in the WTO TRIPS waiver negotiations.

In May, Biden took the world by surprise when he announced US support for the waiver proposal – although only in relation to COVID-19 vaccines. But the European Commission, particularly Germany, has refused to budget.

“The European Union would like to kick the discussions further down the road,” said Dangor, adding that the EU had made it known this week that it was not in favour of a decision on the TRIPS waiver being made at the upcoming WTO Ministerial on 30 November.

Zane Dangor, Special Adviser to South  Africa’s Trade Minister.

“We need commitment on a text from the US that can be tabled and negotiated with South Africa, India and other co-sponsors so that we can have an outcome and move to get to the business of actually ensuring that we get jabs in arms of those who need most and have equitable access,” Dangor told a press briefing organised by Public Citizen.

“Not only do we need to get the WTO waiver done, but we require vaccine recipes to be shared via broad tech transfer to speed expansion of COVID medicine supplies,” added Dangor.

In July, the World Health Organization (WHO) announced that it had established a “tech transfer hub” in South Africa to enable African companies produce mRNA vaccines – but the mRNA manufacturers, Pfizer-BioNTech and Moderna, have refused to join the hub.

Last week, in response to a recent Health Policy Watch question, Pfizer CEO Albert Bourla said: “I’m not sure what is the point of transferring technology that it is going to take years to transfer. And, by the way, this is what we do. I’m not sure I understand what they want, to give it someone else to do?”

European Commission counter-proposal is ‘big air’

Belgian Green Sarah Matthieu, a Member of the European Parliament, believes that the European Commission’s opposition to the waiver is “economic”, based on lobbying and financial support from the pharmaceutical companies. BioNTech is a particularly big donor of Germany’s ruling Christian Democratic Union Party, she added.

“We continue to see the Commission really putting big pharma over people’s health. It continues to push its own proposal, that is, if I can say it bluntly, big air. It’s not going to change anything,” Matthieu told a media briefing on Monday organised by Medecins sans Frontieres (MSF), Health Action International, Public Citizen and Third World Network.

Although the European Parliament has passed a resolution in support of starting text-based negotiations on the waiver, this is continually downplayed by commissioners, she added.

Matthieu said that the German elections on 26 September may shift the power balance it that country and change the position of Germany on the waiver.

US Congressman Ro Khanna said that Biden had shown “strong leadership on the TRIPS waiver” but he now had to “convince our European allies, who are often fond of lecturing the United States about moral responsibility, to live up to theirs”.

Khanna added that the US had been “instrumental in the development of these vaccines”, including by “funding some of the critical research” and “providing purchase agreements that mitigated the risk for pharmaceutical companies”.

Although the US government has indicated it would only support a waiver for vaccines, Khanna told the MSF briefing that this should extend to therapeutics.

“More broadly, we need to have a better system for how we incentivize the production and distribution of drugs to the poor and for issues of that really affect large numbers of population,” said Khanna.

“A purely for-profit model of developing medicines may lead to an over-investment in acne treatment and an under-investment of treatment on some of the biggest diseases.

“Not only do we need a TRIPS waiver, but we need to think about how can we incentivize the development and the production of medicine that actually are affecting the urgent needs of many people in the United States and around the world.”

Waiver debate is about pharma profit, says Stiglitz

Professor Joseph Stiglitz

Nobel laureate and Columbia University economist Professor Joseph Stiglitz described the waiver debate as being about the ability of the drug companies to exercise monopoly power to get substantial profits, rather than a reasonable return on their investment.

“Drug companies’ concern is maximising profits. That’s their business model. And maximising profits means restricting supply because by restricting supply, you increase price, and by increasing price you increase profits,” he stressed.

Referring to Pfizer’s recent talk about selling its vaccine for $175 a dose, Stiglitz said this was based on the belief that there was going to be a vaccine shortage, which would enable the company to extract a monopoly price.

Like Khanna, Stiglitz stressed that the development of the COVID-19 vaccines was an international effort that had involved significant investment from various governments as well as scientists from around the world.

“Germany’s particular view on this is especially peculiar because the German company, BioNTech, has already sold its international rights to Pfizer so the waiver is not even going to affect its profits,” he said, describing the EU’s opposition to the waiver as “objectionable” and “unconscionable”.

Confusion about TRIPS waiver

Stiglitz stressed that there was also confusion about the TRIPS waiver.

“First, this is not the abolition of property rights. [Pharmaceutical companies] still get compensated for using their intellectual property rights. So, it’s not taking away their property rights. Its just saying we are in an emergency, and in this emergency, intellectual property rights have to be available more widely,” Stiglitz told the MSF  briefing.

“Secondly, it’s not even a change in the intellectual framework because, since the beginning of the WTO, we’ve recognised the principle of compulsory licenses. This is effectively just a compulsory license…  to lower transaction costs. Lower transaction costs in the midst of the pandemic, where there’s a kind of urgency that we don’t normally have, is absolutely essential,” he added.

“We’ve enacted voluntary licenses. The world has debated this. It debated it when the WTO TRIPS initially adopted it. It was really debated that in the context of HIV/AIDS, which reaffirmed the principle of compulsory licenses.”

“We are in the midst of what some people call the new cold war. On the one hand, there are authoritarian governments like Russia and China, and then, on the other hand, there are democracies. We would like the democracies to win, but we’re not putting a good face on democracy when we say our democracies put profits over lives.

“Russia has been very actively engaged in vaccine diplomacy. It’s made its vaccine available, say in a country like Argentina. But not only has it made its vaccine available, it’s actually actively engaged in transferring technology and enabling countries to build plants to produce the vaccine. And I’m afraid we’re losing this particular battle.”

Civil society groups demonstrate outside embassies of countries that oppose a temporary WTO patent waiver on COVID-19 health products.

Image Credits: CNBC, Munich Security Conference, Tadeau Andre/MSF .

Non-Violence, also known as The Knotted Gun, is a bronze sculpture by Swedish artist Carl Fredrik Reuterswärd at the United Nations Headquarters in New York.

The 76th session of the United Nations General Assembly (UNGA) opens today (Tuesday 14 September). The UN’s roots lie in determination that the horrors of World War II – millions of lives lost, economic devastation and genocide – should never happen again. 

This year’s General Assembly session is considering multiple global catastrophes, from climate change to the COVID-19 pandemic to growing political instability exacerbated and highlighted by the inequitable burdens of the pandemic. For each, we must consider important technical responses, but we will fail across all of them if we cannot strengthen global cooperation and multilateralism.

The official death toll of COVID-19 has climbed to 4.5 million, and the true toll is much larger, perhaps as high as 15 million lives lost. It’s a stunning indictment of decades of underinvestment in global health security and pandemic preparedness. Without significant progress, we will not only be unable to address COVID-19 sufficiently, we will also be left vulnerable to future threats that experts predict will happen more and more frequently.

The UN system exists because we need global cooperation to forestall disaster and create enduring prosperity by promoting peace and security, fostering strong bonds among nations, and promoting social progress, better living standards and human rights.

We are far from the founding threat and horrors of World War II, but global leaders must rekindle that determination to rise above national interests and face our 21st-century disasters together. 

Strengthening WHO

The World Health Organization (WHO) is the first line of defense against global health emergencies. The General Assembly has to provide greater momentum to the movement to give WHO more authority, independence and resources to quickly address emerging threats, and support its role of strengthening national health systems to prevent illness and deal with shocks. 

The WHO-endorsed idea of a Health Threats Council, to keep countries accountable and committed to working collectively on infectious threats, has merit.

Funds to address global preparedness have already fallen short of pledges; the G20, an intergovernmental forum of 19 countries and the European Union, has not lived up to its commitment of providing $75 billion in international public funding to address gaps in pandemic prevention. 

The General Assembly session will undoubtedly provide a platform for many global leaders to make more pledges, but we must demand action. We will hold our applause for those who make concrete investments.

Until global vaccination rates are high, the virus will continue to circulate, and rapidly evolve new strains that threaten us all. The world’s richest nations have a 1.2 billion dose surplus, while other countries are receiving trickles. Africa’s vaccination rate hovers around 3%.

The assembly must push to operationalize the Access to COVID-19 tools (ACT) Accelerator and its COVAX Facility to its full capacity. 

Set up by WHO to guarantee fair and equitable access for countries through securing commitments from countries with access to vaccines to support those without, true support among rich countries for this effort has been anemic. 

Fewer than 15% of pledges to support COVAX are in place. 

Supporting greater vaccine equity must go beyond a charity model. The UN must generate enough pressure to drive technology transfer from few countries to many. In South Africa, a facility capable of making millions of vaccines lies dormant, and as intellectual property debates of this public good are dragged out, millions of people are dying of COVID-19.

Corporate influence

Addressing the power of corporate interests also lies at the heart of the UN Food Systems Summit, being held alongside the General Assembly meeting. 

The Summit will advance an agenda of promoting access to healthy foods, curbing unhealthy ultra-processed products, and protecting the rights of local farmers and indigenous people. 

This agenda is in peril. We join with the activists who are raising the alarm that global agro-industry and food corporations have too much influence over the agenda and that profits will win out over people. 

We must wrest control of food systems away from profit-driven corporations and return it to local food producers and communities. At both the General Assembly session and the Food Summit, we expect to see the voices of civil society, local food providers and indigenous people elevated. 

This will be essential to reducing the impact of non-communicable diseases, such as heart disease, cancer, and diabetes, which kill 41 million people each year and account for 71% of all deaths globally.

At Vital Strategies, we are working to reimagine public health as central to a sustainable world. Reimagining public health means putting the health agenda at the heart of our civic, social and commercial lives and building a global agenda where cooperation to improve the lives of billions is prioritized. 

Global governance and a UN. General Assembly that builds cooperative action are central to a world where everyone, everywhere can reach the full potential of a long and healthy life.

José Luis Castro is president and CEO at Vital Strategies

 

 

 

 

 

 

 

Image Credits: Matthew TenBruggencate/ Unsplash.

The current COVID-19 vaccines are effective enough against severe disease in the general population that boosters are “not appropriate” even for the Delta variant, according to an expert review by an international group of scientists from the World Health Organization (WHO), the US Food and Drug Administration (FDA) and international universities.

The review, which looked at current evidence from randomised controlled trials and observational studies published in peer-reviewed journals and pre-print servers, was published in The Lancet on Monday.

“Averaging the results reported from the observational studies, vaccination had 95% efficacy against severe disease both from the Delta variant and from the Alpha variant, and over 80% efficacy at protecting against any infection from these variants. Across all vaccine types and variants, vaccine efficacy is greater against severe disease than against mild disease,” according to a press release from The Lancet.

The “Viewpoint” article, led by Dr Philip Krause, of the United States Food and Drug Administration’s Offices of Vaccines Research and Review, and including a number of senior WHO scientists, concluded that results reported from the observational studies it had reviewed, vaccination had 95% efficacy against severe disease both from the delta variant and from the alpha variant, and over 80% efficacy at protecting against any infection from these variants. 

“Current evidence does not, therefore, appear to show a need for boosting in the general population, in which efficacy against severe disease remains high,” concluded the 18 authors, including Dr Ana-Maria Henao-Restrepo, WHO’s Head of Research and Development, Soumya Swaminathan, WHO Chief Scientist, and Mike Ryan, executive director of WHO Emergencies.

 “Taken as a whole, the currently available studies do not provide credible evidence of substantially declining protection against severe disease, which is the primary goal of vaccination,” said Henao-Restrepo, in a press release.

Authors admit data is ‘partial’

The article is based upon a review of nearly two dozen studies that looked at hospitalisation rates among vaccinated people, immune response to the vaccines in the laboratory and among clinical populations over time, and also studies on responses to the brand-new booster shots.

The authors also admit that the data is partial, and changing. 

That’s underlined by the fact that while the review included one paper on initial findings from Israel’s booster programme – one of the first in the world, it failed to note the results cited there, which found a 10-fold decrease in the relative risk of severe illness among people receiving the booster shot 12 days after receiving it, within a cohort of over 1.14 million vaccinated individuals, aged 60 and over. 

Even more recent data from Israel, which has called itself the “world’s laboratory” on vaccine boosters, reflects a stabilisation of infection rates and decline in hospitalised cases as the country experienced the highest infection surges, per capita, in the world. That decline has helped avert a crisis in intensive care and another lockdown, experts say, and can only be attributed to the aggressive administration of booster vaccines – which have now been administered to over one-quarter of the population.,

 

Restating positions already articulated by WHO publicly, the authors argue that instead of administering additional vaccines to people who have already been vaccinated, reaching the unvaccinated is the most important public health imperative as they are both the major drivers of transmission and at the highest risk of serious disease, according to the authors. 

“The limited supply of these vaccines will save the most lives if made available to people who are at appreciable risk of serious disease and have not yet received any vaccine,” added Henao-Restrepo, in the press release.  

Another argument for avoiding boosters right now, she said, is to enable wider vaccine distribution worldwide, so as to hinder the development of dangerous variants. 

“Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated. If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants.” 

Boosting ‘might ultimately be needed’

The authors acknowledge that in the “changing situation” that “boosting might ultimately be needed in the general population because of waning immunity to the primary vaccination or because variants expressing new antigens have evolved to the point at which immune responses to the original vaccine antigens no longer protect adequately against currently circulating viruses”.

They also acknowledge that boosting may already be appropriate for “recipients of vaccines with low efficacy or those who are immunocompromised”.

However, the authors warn that there could be other untoward health risks if boosters are widely introduced too soon, as this could increase the chances of side-effects – and undermine vaccine acceptance.

“Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society. These high-stakes decisions should be based on robust evidence and international scientific discussion,” says Dr Soumya Swaminathan, WHO Chief Scientist and a co-author of the study.

They also note that, even if levels of antibodies in vaccinated individuals wane over time, “this does not necessarily predict reductions in the efficacy of vaccines against severe disease”. 

“This could be because protection against severe disease is mediated not only by antibody responses, which might be relatively short lived for some vaccines, but also by memory responses and cell-mediated immunity, which are generally longer-lived. If boosters are ultimately to be used, there will be a need to identify specific circumstances where the benefits outweigh the risks,” they argue.

Aside from the WHO and FDA, other authors in the study were from the University of Washington (USA), University of Oxford (UK), University of Florida (USA), University of the West Indies (Jamaica), University of Bristol (UK), Universidad Nacional Autonoma de Mexico (Mexico), Wits Reproductive Health and HIV Institute (South Africa), Universite de Paris (France), and the INCLEN Trust International (India).

“WHO’s Strategic Advisory Group of Experts on Immunization,(SAGE), which develops WHO’s immunisation policy, is actively reviewing all the evidence including the data and this issue,” according to the Lancet press release, which notes that the paper does not constitute a formal policy position for WHO.

 

Image Credits: Roger Starnes / Unsplash.

Integration of care is important for patients’ wellbeing.

Health services in low and middle-income countries have yet to adapt to their growing burden of non-communicable diseases (NCDs) and still prioritise infectious diseases, according to a new report launched on Thursday by the NCD Alliance.

Treatment “silos” for HIV and tuberculosis need to be transformed into integrated universal healthcare services to better serve people in LMICs, many of whom are living with both infectious diseases and NCDs, according to the report.

“COVID-19 has brought about a greater recognition that the long-held distinctions between infectious and non-communicable diseases are not as clear cut as once thought – those with chronic conditions have a significantly higher risk of hospitalisation or death from the virus,” according to the NCD Alliance. 

The vast majority of people who have become seriously ill or died from COVID-19 had an underlying condition, particularly hypertension, cardiovascular disease and diabetes, it notes.

Integrated care ‘is the future’

“We urgently need a reset of healthcare delivery in poorer countries that actually reflects the needs of those who need it most,” said Katie Dain, CEO of the NCD Alliance. 

“Integrated care is the future of healthcare. The reality today is that ever more people are living with multiple chronic conditions. This needs to be better recognised in health systems. 

Dain added that infectious diseases and NCDs were entwined: “People living with HIV have a significantly higher risk of cardiovascular disease and some cancers. People living with TB are much more susceptible to diabetes and vice-versa. 

“Hypertensive disorders and gestational diabetes affect many pregnancies, risking potential lifelong health impacts for both mother and child if not effectively treated.”

“LMICs are experiencing a rapid transition from population disease profiles shaped by communicable diseases and conditions impacting mothers and their children, to those dominated by NCDs and injuries. Today, 85% of people dying from NCDs between ages 30 and 70 are in LMICs,” according to the NCD Alliance.

One in three diseases among the poorest billion people in the world are NCDs, according to the Lancet NCDI Poverty Commission.

Cardiovascular diseases account for most NCD deaths (17.9 million people annually), followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). These four groups of diseases account for over 80 percent of all  NCD deaths before the age of 70.

“Health centres that reflect this changing epidemiology are the future,” said Dain. “But this will also mean that we have to change the way we do business. The COVID-19 pandemic has been catastrophic for people living with NCDs and it is clear we need a health infrastructure in LMICs that is fit for purpose if we are to build back better.”

HIV, TB funding influences health system

The report’s lead author, Dr Gill Schierhout from the George Institute for Global Health, said that many LMIC health systems were still influenced by funding for HIV, TB, malaria and maternal health.

“The shape of this [funding] has critical impacts on the health care available – or not available – for the growing number of people who are living with NCDs in LMICs,” said Schierhout.

The report was based on an online survey that was sent to health workers in LMIC. Survey respondents identified that there were particular challenges posed by staffing siloes, and organisational ambivalence around the integration effort.

In addition, specialist managers of global health initiatives are sometimes “well versed in disease-focused areas, but not as well versed in whole-of-person care or primary health care. Therefore, programmes often struggle to gain the necessary management support”, according to the report.

However, the report documents a number of integration  successes. In Zambia, for example,  a cervical cancer screening has been integrated into an HIV care programme. It modelled that, for every 46 HIV-positive women screened, a woman’s life was saved who otherwise would likely have died of undetected cervical cancer.

More than a decade ago Ministers of Health resolved at the first UN High-Level Meeting on NCDs to “encourage the development, integration and implementation of vertical programmes, including disease-specific programmes, in the context of integrated primary health care”. 

“However, progress in this area has been patchy at best,” noted the NCD Alliance.

 

 

Image Credits: NCD Alliance, WHO/A. Loke.

Ethiopia vaccines
AstraZeneca COVID-19 vaccine arrive at Bole International Airport in Addis Ababa, Ethiopia, in March.

As Africa prepares to get even fewer COVID-19 vaccines than expected in the coming months thanks to the supply shortage at COVAX, the continent is also battling with vaccine hesitancy – exacerbated by the lack of vaccinated role models.

Africa could receive 155 million fewer vaccines than expected this year from the global vaccine platform, COVAX, which announced on Wednesday that it has had to cut its supply forecast by 25% as it has been affected by export bans, particularly from India, bilateral deals between manufacturers and countries, production challenges and delays in vaccine regulatory approval. (COVAX had previously said it will provide 520 million doses to the WHO Afro region by the end of the year.)

As a result, said Dr Matshidiso Moeti, head of the World Health Organization (WHO) Africa, the continent would have to continue to rely on economically crippling lockdowns, and other public health prevention measures instead of vaccinations to control the pandemic.

However, Moeti also conceded that the continent was facing vaccine hesitancy in some countries, notably the Democratic Republic of Congo (DRC) – which is also battling a meningitis outbreak.

“It’s true that vaccine rejection, denial, has been a strong feature of the response in the DRC,” Moeti told a WHO Africa media briefing on Thursday. 

“The demand was so little that the country, at some point had to redistribute some vaccine supplies that it had been provided for to other countries.

“Some surveys have shown that [vaccine hesitancy] has started to shift in other countries as the vaccines have been rolled out more and more people are interested now in getting vaccinated,” she added.

This was partly because people who have already been vaccinated can act as “role  models” to show that vaccines are safe, can prevent severe illness and death, she said.

Dr Matshidiso Moeti, head of the World Health Organization Africa region.

Only 20 African countries may reach 10% target this month

But vaccinated Africans currently make up a tiny minority.

“As of today, Africa as a whole has received around 138 million doses only,” said Dr Richard Mihigo, WHO’s Program Area Manager for Immunisation.

 “Only around 40 million people have received the two doses that are required to be fully vaccinated, and this represents merely 3% of the African population.When you look at sub-Saharan Africa, it’s around 1.7%,” added Mihigo.

Fewer than 20 out of the 54 African countries were likely to reach the WHO target of 10% of their population vaccinated by the end of this month, he added.

However, Mihigo said that despite the COVAX shortfall, vaccine supply was fluid and the continent could still get the vaccines it needed to vaccinate 40% of Africans by the end of the year, WHO’s next target.

Meanwhile, Moeti stressed that increasing vaccine supply was the biggest priority for the country.

She noted that while COVAX had recently supplied around five million vaccines to Africa, three times as many doses – 15 million had been thrown away in the US due to wastage.

“This is enough vaccines to cover everyone over 18 years in Liberia, Mauritania, and the Gambia,” she observed. “Every dose is precious and has the potential to save a life.”

She noted that, while high-income countries have pledged to share one billion doses globally, and so far 120 million doses have been released.

Prioritize vaccine equity

“Manufacturers are now producing 1.5 billion COVID vaccine doses globally each month, and two billion doses are required to reach 40% of people in every country. If producing countries and companies prioritise vaccine equity, this pandemic, can be over quickly,” she noted.

However instead, COVAX had announced that its shipment forecast for the rest of the year had been revised downwards by 25% “in part because of the prioritisation of bilateral deals over international solidarity”, she said. 

“G20 Health Ministers this week expressed their support for the global 40% vaccination target. This goodwill needs to be accompanied by concrete actions and financing for the global fight against COVID-19, to succeed,” she added.

Image Credits: UNICEF, WHO.

COVID booster vaccines have gained traction in several countries – US, Israel, Germany, UK, and others, but low- and middle-income countries lag significantly behind in shots.

The World Health Organization (WHO) has called for its global moratorium on COVID-19 boosters to be extended until the end of the year to enable vaccines to be directed to countries that have not yet been able to reach their vulnerable citizens.

“A month ago, I called for a global moratorium on booster doses at least until the end of September to prioritise vaccinating the most at-risk people around the world who are yet to receive their first dose,” WHO Director-General Tedros Adhanom Ghebreyesus told the body’s media briefing on Wednesday.

“There has been little change in the global situation since then, so today I am calling for an extension of the moratorium until at least the end of the year, to enable every country to vaccinate at least 40 percent of its population.”

The WHO’s global target is for every country to vaccinate at least 10% of its population by the end of this month, at least 40% by the end of this year and 70% of the world’s population by the middle of next year – but the September target so far is likely to be missed due to the failure of rich countries to donate sufficient doses to low- and middle-income countries.  And current commitments to COVAX, the WHO co-sponsored global vaccine facility, are running several hundred million doses short of the 40% end-year goal. 

Dr Kate O’Brien

Dr Kate O’Brien, WHO’s director of immunisations, also stressed that there was neither scientific consensus nor enough evidence to support giving COVID-19 boosters.

“We’re not asking [countries] to withhold something for which there is a strong set of evidence,” said O’Brien. “The vaccines are holding up very, very well against the severe end of the disease spectrum. The actual focus of the vaccine programme is to prevent severe disease, hospitalizations and deaths, and we see in the evidence that, in fact, the vaccines are performing extremely well over time, and against the variants,” she said. 

According to a technical report issued by the European Centre for Disease Prevention and Control (ECDC) last week, “based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population” but that ”additional doses should already be considered for people with severely weakened immune systems as part of their primary vaccination”.

“We will continue to watch the evidence very carefully, but our expert advisory committees continue to see that there is not a compelling case to move forward with a generalised recommendation for booster doses,” added O’Brien.

No more promises, just vaccine delivery

Tedros hit out at high-income countries that have promised to donate more than one billion doses as “less than 15 % of those doses have materialised”. 

“Manufacturers have promised to prioritize COVAX and low-income countries. We don’t want any more promises. We just want the vaccines,” Tedros added.

Although 5.5 billion vaccine doses have been administered globally, 80% have been administered in high- and upper-middle-income countries, according to the WHO.

Reiterating his weekend appeal to G20 health ministers, Tedros said that “the world’s largest producers, consumers and donors of vaccines, the world’s 20 leading economies, hold the key to vaccine equity and ending the pandemic”.

They could do so by swapping their near-term vaccine deliveries with COVAX, fulfilling their dose-sharing pledges by the end of this month and “facilitating the sharing of technology, know-how and intellectual property to support regional vaccine manufacturing”, he added.

WHO’s Bruce Aylward

Dr Bruce Aylward, the WHO representative on COVAX, said that despite promises made by the G7 and others, the global vaccine platform had to reduce its supply forecast this week as there had been a 25% reduction in the number of doses that will go through COVAX – unless there is urgent action by the world’s G20 countries and vaccine manufacturers. 

“People have come out and said, ‘Well, it’s only 100 million doses if we do boosters’, but we’ve just had to downgrade supply by a few 100 million doses. It makes a real difference in the face of scarcity,” added Aylward.

“To get all the world to 40% [vaccination] coverage in every single country requires two billion doses of vaccine,” he added.  

According to its latest Supply Forecast, COVAX expects to have access to 1.425 billion doses of vaccine in 2021 “in the most likely scenario and in the absence of urgent action by producers and high-coverage countries to prioritize COVAX”.

COVAX supply forecast, 8 September 2021

COVAX added that its work was being hampered by “export bans, the prioritisation of bilateral deals by manufacturers and countries, ongoing challenges in scaling up production by some key producers, and delays in filing for regulatory approval”.

Tedros ‘appalled’ by IFPMA comments

Tedros also lashed out directly at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for comments made in an media briefing on Tuesday.

He complained that the IFPMA was calling for dose-sharing with poorer nations – but only after rich countries had vaccinated virtually everyone who wanted a jab.

“Yesterday, the IFPMA said that G7 countries now have enough vaccines for all their adults and teenagers, and to offer booster doses to at-risk groups, and that manufacturing scale-up should now shift to delivering global vaccine equity, including dose sharing,” said Tedros.

“When I read this, I was appalled,” said Tedros. “In reality, manufacturers and high-income countries have long had the capacity to, not only vaccinate their own priority groups, but to simultaneously support the vaccination of those same groups in all countries.

“We have been calling for vaccine equity from the beginning, not after the richest countries have been lower-middle-income- and lower-middle income countries are not the second or third priority. Their health workers, older people, and other at-risk groups have the same right to be protected. I will not stay silent when the companies and countries that control the global supply of vaccines think the world’s poor should be satisfied with leftovers,” Tedros said.

In the IFPMA statement, the pharmaceutical body stated that: “The biopharmaceutical industry continues to call for dose sharing and renew its commitment to work with governments to support their efforts.

“From now on, G7 countries have sufficient stocks of doses to vaccinate adults, teenagers and roll out boosters programmes to protect the most at-risk groups as well as substantially increase the number of doses available to low- and lower-middle-income countries. Political leadership is critical to enable dose deliveries as quickly as possible.

“Reducing the toll of the pandemic on lives and livelihoods requires equitable access to vaccines and country readiness for vaccination.”

WHO Director General Dr Tedros Adhanom Ghebreyesus.

Aylward, meanwhile, took a less combative position, recognising that vaccine inequity was no longer an issue of supply constraints.

“We had the IFPMA came out yesterday and said ‘Look, global production is 1.5 billion doses a month now’. The absorptive capacity of the world is less than a billion right now… So, the volumes are there. This is a fixable problem, but it’s only going to get fixed if the political will and the will of the manufacturers come together to solve it,” he said.

Israel, currently facing one of the highest infection rates in the world due to a Delta variant surge, has already implemented boosters shots for any residents who got their jabs more than five months ago.  And the White House has also announced it would begin offering boosters in September for everyone immunised eight months ago or longer – although regulatory authorities are still debating authorization of the plan. Several other countries including France, Germany, Thailand and the United Arab Emirates are offering boosters.

But Aylward noted that many other countries had already consulted the WHO on whether booster policies can be delayed. 

“Some countries may be going ahead with [booster] decisions, others may not. But our role is to make sure that we put forward the strongest possible arguments for the way out of this pandemic, and the way out is an extended moratorium because, since the last time we called for it, the equity gaps have got greater, the amount of vaccine available in low-income countries has gone down,” he added.

Recognise all WHO-listed vaccines

Tedros also condemned the refusal of some countries to allow travellers who have been fully vaccinated with a vaccine that has WHO Emergency Use Listing (EUL) entry on the basis that their vaccines have not been approved by their national regulators.

“WHO Emergency Use Listing follows a rigorous process based on internationally recognized standards. All vaccines that have received WHO Emergency Use Listing are safe and effective in preventing severe disease and death, including against the Delta variant,” said Tedros, urging all countries to recognize all vaccines with WHO EUL.

This follows reports that some European countries are still not allowing travellers vaccinated with Covishield, the AstraZeneca vaccine produced by the Serum Institute of India, to enter their countries – even though the European Union has approved the AstraZeneca vaccine made elsewhere.

 

Image Credits: Marco Verch/Flickr.